Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27096703 | 0.78 | DGAT1 (0.38) | — | |
| SCHEMBL17276033 | 0.77 | — | — | |
| SCHEMBL3327476 | 0.77 | DPP4 (0.37) | ALDH1A1DPP4DPP7 | |
| SCHEMBL14888691 | 0.76 | CYP1A2 (0.34) | — | |
| SCHEMBL476448 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TP53 | |
| SCHEMBL14783914 | 0.75 | — | — | |
| SCHEMBL29787042 | 0.75 | — | — | |
| SCHEMBL345818 | 0.74 | FFAR3 (0.37) | ALDH1A1TP53 | |
| SCHEMBL21645116 | 0.74 | SLC6A1 (0.33) | DPP4DPP7 | |
| SCHEMBL14957117 | 0.74 | SLC6A1 (0.33) | DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200283397-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3256218-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2016130952-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-1901746-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283397-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | ALDH1A1 734/4885TP53 524/4885DPP4 4367/4885 |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | ALDH1A1 734/4885TP53 524/4885DPP4 4367/4885 |
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | ALDH1A1 734/4885TP53 524/4885DPP4 4367/4885 |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | ALDH1A1 734/4885TP53 524/4885DPP4 4367/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | ALDH1A1 734/4885TP53 524/4885DPP4 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.